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Monoclonal antibody SF8/5E11, which recognizes the transmembrane protein (TMP) of simian immunodeficiency virus of macaque monkeys (SlVmac), displayed strict strain specificity. It reacted with cloned and
uncloned SIVmac251 but not with cloned SIVmacl42 and SIVmac239 on immunoblots. This monoclonal
antibody neutralized infection by cloned, cell-free SIVmac251 and inhibited formation of syncytia by cloned
SIVmac251-infected cells; these activities were specific to cloned SIVmac251 and did not occur with the other
viruses. Site-specific mutagenesis was used to show that TMP amino acids 106 to 110 (Asp-Trp-Asn-Asn-Asp)
determined the strain specificity of the monoclonal antibody. This strain-specific neutralizing determinant is
located within a variable region of SIVmac and human immunodeficiency virus type 2 (HIV-2) which includes
conserved, clustered sites for N-linked glycosylation. The determinant corresponds exactly to a variable, weak
neutralizing epitope in HIV-1 TMP which also includes conserved, clustered sites for N-linked glycosylation.
Thus, the location of at least one neutralizing epitope appears to be common to both SlVmac and HIV-1. Our
results suggest a role for this determinant in the viral entry process. Genetic variation was observed in this
neutralizing determinant following infection of a rhesus monkey with molecularly cloned SIVmac239; variant
forms of the strain-specific, neutralizing determinant accumulated during persistent infection in vivo. Selective
pressure from the host immune response in vivo may result in sequence variation in this neutralizing
determinant.

yet been identified. The extent to which neutralizing
epitopes in SIV correspond to those in HIV-1 is not known.
In this report, we identify an SIVmac neutralizing determinant defined by monoclonal antibody (MAb) SF8/5E11
and show that it corresponds to a neutralizing epitope in
HIV-1 TMP. The determinant is located in a variable region
of the TMP which includes conserved, clustered sites for
N-linked glycosylation. Furthermore, genetic drift in this
neutralizing determinant was observed in a persistently
infected rhesus monkey that was previously inoculated with
molecularly cloned SIVmac239 and had a strong antibody
response to the infecting virus.

The simian immunodeficiency viruses (SIVs) are nonhuman primate lentiviruses related to the human immunodeficiency viruses (HIV-1 and HIV-2), the causative agents of
AIDS in humans. SIV has been isolated from several species
of Old World primates, including rhesus monkeys (SIVmac)
(6), African green monkeys (SIVagm) (35), sooty mangabey
monkeys (SIVsm) (12, 33), and mandrills (SIVmnd) (47). The
extensive similarity of SIV to HIV in genetic organization
and biological properties suggests that SIV systems are
ideally suited for study of AIDS pathogenesis and vaccine
strategies. Analysis of nucleotide sequence homology and
antigenic cross-reactivity has demonstrated that SIVmac
and SIVsm are closely related to HIV-2 (3, 9, 15, 18). The
three viruses SIVmac, SIVsm, and HIV-2 likely comprise a
discrete subgroup of primate lentiviruses. Thus, SIV genetic
relationships also provide clues to the evolution, origin, and
possible interspecies transmission of lentiviruses in primates.
One of the striking features of HIV-1 is the extent of
genetic variation among virus isolates (8, 16, 53). Variation is
largely concentrated in the outer membrane protein (gpl20)
of the envelope (8, 16, 45), which is a major target of host
immune responses. The transmembrane protein (TMP) of
HIV-1 is relatively conserved in its sequence (16, 45). A
major neutralizing epitope in HIV-1 has been localized to
one of the variable regions of gpl20, the V3 cysteine loop
(14, 37, 40). In addition, neutralizing epitopes have been
identified in other regions of the gpl20 molecule (19, 20) and
in the TMP (4, 5, 20). Neutralizing epitopes in SIV have not

*

MATERIALS AND METHODS
MAb. MAb SF8/SE11, which recognizes the TMP of
SIVmac, was previously isolated by using detergent-disrupted uncloned SIVmac251 as an immunogen (49). The
immunoglobulin subclass of the MAb was determined to be
Gl, and it was used as mouse ascitic fluid.
Radiolabeling of cells and immunoprecipitation assay.
CEMx174 cells infected with cloned SIVmac251 were labeled with [35S]methionine, and immunoprecipitations were
performed as previously described (48). For tunicamycin
treatment, cells were suspended for 1 h in methionine-free
medium containing 3 ,ug of tunicamycin per ml and subsequently labeled for 5 h at 37°C with [35S]methionine (200
,uCi/ml). The same concentration of tunicamycin was maintained during the labeling period. Labeled cells were washed
and disrupted in phosphate-buffered saline containing 0.1%
sodium dodecyl sulfate (SDS), 1% Triton X-100, and 0.5%
sodium deoxycholate. The lysates were preabsorbed with
protein A-Sepharose bound to rabbit antiserum to mouse K
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light chains (K-PAS) and then clarified. Radioimmunoprecipitation analysis was performed by the addition to 1 ml of
the labeled extract with 1 ,ul of the MAb and 0.2 ml of a 10%
suspension of K-PAS. The samples were incubated for 18 h
at 4°C. Immunoprecipitates were resuspended in Laemmli
sample buffer and analyzed by SDS-polyacrylamide gel
electrophoresis (PAGE).
Neutralization assay. Cell-free virus neutralizing activity of
the MAb was analyzed by incubating 100 ,ul of a 1:50 dilution
of cloned SIVmac (approximately 200 tissue culture infectious doses) with 25 RI of heat-inactivated SF8/SE11 for 1 h
at 37°C and inoculating the mixture onto 5 x 105 CEMx174
cells or HUT-78 cells in 1 ml of RPMI 1640 medium
containing 10% fetal bovine serum, 1% heat-inactivated
MAb SF8/SE11, and penicillin-streptomycin (complete
RPMI 1640 medium). After 24 h, the cells were washed once
and resuspended in complete RPMI 1640 medium. Resultant
SIV production was monitored at the indicated times by
measurement of reverse transcriptase activity in the culture
supernatant (6).
Syncytium inhibition assay. Syncytium inhibition assays
were performed in 96-well microtiter plates by mixing 2.5 x
104 CEMx174 cells with 104 SIVmac-infected CEMx174 cells
in the presence or absence of 10 RI of MAb SF8/5E11 in a
total volume of 100 ,u. Plates were then incubated for 24 to
48 h at 37°C, and the extent of syncytium formation in each
well was evaluated by microscopic examination.
SIVmac molecular clones. The infectious lambda clones
designated SIVmacl42, SIVmac251, and SIVmac239 have
been described previously (3, 25, 34). The SIVmac239
lambda clone has been subcloned into two separate DNA
segments by using a unique, centrally located SphI site (24).
This generated two pBS (Stratagene) plasmid subclones
containing the left half (p239SpSpS') and the right half
(p239SpE3') of the viral genome.
Oligonucleotide synthesis. Oligodeoxyribonucleotides were
synthesized by the phosphoramidite method on a Cyclone
DNA synthesizer (Biosearch), using reaction columns containing derivatized CPG support (Milligen) and purified with
C18 Sep-Pak cartridges (Millipore).
Construction of mutants by PCR. Mutants in the viral
envelope gene were derived from plasmid p239SpE3' by
site-specific mutagenesis using polymerase chain reaction
(PCR) (41). PCR amplifications were performed with an
automated DNA Thermal Cycler (Perkin-Elmer Cetus) for
20 cycles (each consisting of a 1-min 94°C denaturation, a
2-min 55°C annealing, and a 5-min 72°C extension step),
followed by a single 10-min extension at 72°C. Then 1 ,M
each primer, 2.5 U of Taq polymerase, 1.5 mM MgCl2, and
200 ,uM each deoxynucleoside triphosphate were used in the
PCR reaction mixture.
Site-specific mutagenesis by overlap extension (SOE) requires introduction of nucleotide changes within oligonucleotide PCR primers and a secondary PCR amplification to
incorporate changes into an internal site within the amplified
DNA fragment (21, 22). Two mutants with defined substitutions within the envelope TMP of SIVmac239 were generated by using pairs of complementary mutagenic oligonucleotide primers representing nucleotides 8491 to 8517 (38).
Primer 5'-CCA AAG TGG AAC AAT GAT ACT TGG
CAA-3' and its complementary oligonucleotide were used to
generate mutant p239SpE3'tm-1, and primer 5'-CCA GAT
TGG AAC AAT GAT ACT TGG CAA-3' and its complement generated mutant p239SpE3'tm-2. Underlined letters
identify nucleotide changes that were introduced. The outer
set of oligonucleotide primers consisted of 5'-AGTGCA
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GAGGTGGCAGAACT-3' (8050 to 8069) and 5'-TGTCCCT
CACAAGAGAGTGAGCTCAAGCCC-3' (9220 to 9249).
Two segments (8050 to 8517 and 8491 to 9249) were generated in separate reactions, each containing one set of outer
and inner mutagenic primers and 0.1 ,ug of plasmid
p239SpE3'. For overlap extension by PCR, amplified products from the first round of PCR which shared overlapping
sequences at the ends to be joined were purified from an
agarose gel and mixed in a subsequent PCR reaction containing additional outer primer pairs. The resulting PCRgenerated recombinant products were purified from an agarose gel and restricted with ClaI and BglII, and the
fragments were inserted into the ClaI-BglII site of
p239SpE3'. Since the recombinant plasmid (p239ABglII) lost
the 2.8-kb BglII fragment containing the 3' long terminal
repeat region through the cloning step, the fragment was
reinserted to generate p239SpE3'tm-1 and p239SpE3'tm-2.
The nucleotide sequence surrounding the site of SOE in the
mutant clones was confirmed by primer-directed dideoxychain termination sequencing (42).
DNA transfection. An SIVmac239 left-half clone
(p239SpSpS') was ligated with parental and mutant right-half
clones after digestion with SphI and transfected into
CEMx174 cells with DEAE-dextran (34). Virus replication
was monitored by measurement of reverse transcriptase
activity in the culture supernatant. Virus particles concentrated from the culture supernatant were used for immunoblot analysis (27).
Analysis of envelope variability in vivo. Total cell DNA was
prepared from peripheral blood mononuclear cells at 69 and
93 weeks postinfection and from a lymph node biopsy taken
at 69 weeks from a rhesus monkey persistently infected with
molecularly cloned SIVmac239. A fraction of the lymph
node taken at 69 weeks and a fraction of the peripheral blood
mononuclear cells taken at 93 weeks were each cocultivated
with CEMx174 cells for a total of 51 and 41 days, respectively, and the recovered virus was used to prepare Hirt
supernatant DNA. The total cell and Hirt supernatant DNAs
were used as templates in PCR to specifically amplify
full-length env sequences between nucleotides 6544 and 9249
(38). For the total cell DNAs, two rounds of 30 PCR cycles
were performed. The first round of PCR was performed with
an outer set of oligonucleotide primers (6474 to 6493 and
9279 to 9298), while the second round was performed with an
inner set of primers (6544 to 6573 and 9220 to 9249) complementary to the amplified product of the first round. For the
Hirt supernatant DNAs, only the inner set of primers was
used in one round of PCR. The inner primers contained SstI
sites for cloning. The PCR reaction conditions were in
accordance with those of the manufacturer (Perkin-Elmer
Cetus), and the following cycle profile was used: denaturation at 94°C for 1 min, annealing at 55°C for 2 min, and
extension at 72°C for 3 min. An autoextension of 10 s was
added to each PCR cycle, and a 10-min final extension at
72°C was added to the last cycle. The 2.7-kb amplified env
fragments were restricted with SstI and cloned into pBS(Stratagene) for subsequent double-stranded DNA sequence
analysis.
Nucleotide sequence accession number. The SIVmac239
sequence reported here has been filed with the GenBank
data base under accession number M33262.
RESULTS
Strict strain specificity of MAb SF8/5E11. Previously it was
demonstrated that MAb SF8/SE11 reacted with the TMP of
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FIG. 1. Immunoprecipitation of SIVmac251 unglycosylated envelope precursor with MAb SF8/5E11. CEMx174 cells infected with
cloned SIVmac251 were treated with no inhibitor (lane 1) or 3 ,ug of
tunicamycin per ml (lane 2) and labeled for 5 h with [35S]methionine.
Radiolabeled protein in the cell lysates was immunoprecipitated
with MAb SF8/SE11 and analyzed by SDS-PAGE.

uncloned SIVmac251 but did not cross-react with SIVsm or
SIVmne (49). Therefore, the MAb seemed to recognize a
specific epitope in SIVmac TMP. The MAb predominantly
precipitated envelope precursor (gp160) from metabolically
labeled CEMx174 cells infected with cloned SIVmac251
(Fig. 1, lane 1). After tunicamycin treatment of the same
cells to block the synthesis of the dolichol phosphate-linked
oligosaccharide precursor (10), the MAb precipitated a polypeptide of 80 kDa, which is approximately the predicted size
of the unglycosylated form of the envelope precursor of
SIVmac251 (Fig. 1, lane 2). Therefore, SF8/5E11 recognized
an epitope located in the protein backbone of SIVmac TMP,
and carbohydrates were apparently not involved in the MAb
recognition.
Reactivity with three molecular clones of SIVmac was
analyzed by immunoblotting to examine whether the epitope
recognized by the MAb was commonly present in SIVmac
(Fig. 2). The SIVmacl42 and SIVmac251 cloned viruses
have truncated forms of TMP (28 to 30 kDa; Fig. 2),
reflecting the presence of in-frame stop codons in their TMP
coding regions (3, 27, 34); the SIVmac239 infectious clone
does not have a premature in-frame stop codon in its TMP
coding region, and it produces virus with full-length (41-kDa)
TMP following short-term culture in the human CD4-positive cell line CEMx174 (Fig. 2) (27). The MAb reacted
strongly with the 30-kDa TMP of cloned SIVmac251. However, the MAb reacted only very weakly with TMP of cloned
SIVmacl42 (the reactivity cannot be seen in Fig. 2), and it
did not react detectably with cloned SIVmac239.
To determine whether the epitope recognized by the MAb
in the TMP was expressed on the surface of cells infected
with SIVmac251, we performed a live-cell immunofluorescence assay. CEMX174 cells infected with SIVmac251 were
incubated with a 1:100 dilution of SF8/SE11, washed, and
then incubated with fluorescein isothiocyanate-conjugated
goat antimouse immunoglobulin G. Cells were further
washed and examined under a fluorescence microscope.
Expression of the epitope recognized by the MAb was
clearly detected on the surface of the infected cells (data not
shown).
To examine potential biological activity of the MAb, two

FIG. 2. Strain-specific reactivity of MAb SF8/SE11 to cloned
SIVmac251 TMP by immunoblotting. The SIVmacl42, SIVmac239,
and SIVmac251 cloned viruses were concentrated from the culture
supernatants and analyzed for immunoblot reactivity, using SIVmac-positive rhesus monkey sera (Pos. Cont) and MAb SF8/SE11.
The size of each TMP is indicated.

assays were performed. In a cell-free virus neutralization
assay (Fig. 3), cloned SIVmac251 and cloned SIVmac239
were used to infect HUT-78 cells and CEMx174 cells,

respectively. MAb SF8/SE11 exhibited neutralizing activity
with cloned SIVmac251 cell-free virus, but it did not neutralize cloned SIVmac239 virus. The MAb was also examined for its ability to inhibit syncytium formation between
uninfected and infected CEMx174 cells (Table 1). Inhibition
of syncytium formation by SF8/SE11 was also strain specific.
The MAb inhibited syncytium formation with cloned SIVmac251-infected cells, but it did not prevent syncytium
formation with cloned SIVmacl42- and cloned SIVmac239infected cells. Thus, the strict strain specificity of the MAb
with respect to reactivity on immunoblots paralleled results
with the biological assays.
Identification of determinants of strain specificity. These
data indicated that the MAb recognized a specific neutralizing determinant within a variable region of the SIVmac
TMP. We compared the TMP sequences of the three SIV
mac infectious clones to obtain insight into the epitope
recognized by MAb SF8/SE11. The sequences of SIVmacl42
TMP (3) and SIVmac239 TMP (27) have been previously
published. We sequenced DNA in the TMP region of the
SIVmac251 infectious clone and compared it with the previously published sequences (Fig. 4). Sequence differences at
only two sites could possibly explain the specificity of the
MAb. Valine at TMP amino acid (aa) 172 was unique to the
SIVmac251 infectious clone. However, this amino acid is
located in the putative membrane-spanning domain and
would not be a likely candidate for recognition by the MAb.
Aspartate at TMP aa 110 was also unique to the SIVmac251
infectious clone, so we focused our additional experiments
on this region. To verify that the strain specificity of the
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FIG. 3. Cell-free virus neutralizing activity of MAb SF8/SE11. Approximately 200 tissue culture infectious doses of cloned SIVmac251 and
SIVmac239 were incubated with (-) or without (OI) MAb SF8/5E11 for 1 h at 370C and inoculated onto cultured cells as described in Materials
and Methods. Resultant SIV production was monitored by assay of reverse transcriptase activity in the culture supematant.

MAb was due to the amino acid differences in this region,
SOE was used to change individual TMP amino acids in
SIVmac239 at positions 110 and 106. In SIVmac239tm-1, the
Glu at TMP aa 110 in SIVmac239 was changed to Asp, i.e.,
the amino acid that is present at this location in SIVmac251
(Fig. SA). This was accomplished by changing a G to T at bp
8508 in the SIVmac239 sequence. Since SIVmac239 also
differs from SIVmac251 at TMP aa 106, a second mutant of
SIVmac239, called SIVmac239tm-2, was constructed in
which both Glu-110 -* Asp and Lys-106 -* Asp changes
were introduced (Fig. SA). The strategy for site-specific
mutagenesis is outlined in Fig. 6 and in Materials and
Methods. The mutant forms were confirmed by DNA sequencing. Plasmid DNAs with the described mutations were
transfected into CEMx174 cells, and virus production was
monitored by assay of reverse transcriptase activity. The
mutant viruses were fully replication competent. Virus particles were concentrated from the culture supernatant 2
weeks after transfection and analyzed by immunoblotting.
Although the predicted molecular weights of the TMP polypeptide backbones of SIVmac239, SIVmac239tm-1, and
SIVmac239tm-2 are essentially the same, SIVmac239tm-1
TMP was approximately 2 kDa smaller than wild type and
SIVmac239tm-2 by SDS-PAGE (Fig. 5B). SIVmac239tm-1
showed only weak reactivity to MAb SF8/SE11. However,
SIVmac239tm-2 with changes at both positions 106 and 110
reacted strongly with the MAb, as strongly as SIVmac251
(Fig. SB). Thus, the TMP amino acid sequence Asp-TrpAsn-Asn-Asp at position 106 to 110 determines the strainspecific reactivity and neutralization by SF8/SE11.
Samples (1 VLg) of overlapping peptides 25 amino acids in
length spanning this region (SIVmac251 TMP aa 86 to 110
and 103 to 127) were spotted onto nitrocellulose and tested
for reactivity to MAb SF8/5E11. SIVmac-positive rhesus
TABLE 1. Syncytium inhibition by SF8/SE11
Cloned virus

SIVmac251
SIVmac239
SIVmacl42

Syncytium formationa
+SF8/5E11

-SF8/5E11

++
+++

+++
++
+++

a CEMx174 cells were mixed with cloned SIVmac-infected CEMx174 cells
in the presence or absence of MAb SF8/5E11. The extent of syncytium
formation was evaluated at 48 h.

monkey sera reacted with both peptides. However, specific
reactivity of the MAb to these peptides containing the 106 to
110 region of SIVmac251 could not be demonstrated (data
not shown). A lambda gtll expression library containing
100-bp average inserts from the full-length genome was
screened by plating approximately 8 x 104 phages onto
Escherichia coli Y1090 cells. After plaques developed, nitrocellulose filters impregnated with isopropyl-p-D-thiogalactopyranoside (IPTG) were overlayed and incubated overnight. The filters were blocked and reacted with SF8/5E11
for 1-h. SF8/SE11 failed to react positively with any of the E.
coli recombinant proteins (data not shown).
CEMx174 cells were infected with parental cloned
SIVmac239 and with mutants SIVmac239tm-1 and SIVmac
239tm-2, and by 4 weeks more than 80% of the cells
expressed viral antigens. The virus-infected cells were cocultivated with uninfected CEMx174 cells in the presence or
absence of MAb SF8/SE11. Similar extents of syncytium
formation were observed in cultures infected with parental
SIVmac239 and mutants SIVmac239tm-2. However, cells
infected with SIVmac239tm-1 showed considerably weaker
syncytium formation (Table 2). Inhibition of syncytium
formation with SIVmac239tm-2-infected cells by the MAb
further demonstrated that TMP amino acids from 106 to 110
were critical determinants of epitope recognition by the
MAb.
Genomic variation. This strain-specific neutralizing determinant is located within a variable region of SIVmac which
includes three potential sites for N-linked glycosylation
(N-X-S or N-X-T, where X is any amino acid) (Fig. 7). The
TMP amino acid sequences are generally well conserved
among SIVmac, SIVsm, and HIV-2 (75 to 89% overall
homology); this conservation is especially evident in the
amino-terminal region, which shows 90% identity (18, 54).
The three potential N-linked glycosylation sites are completely conserved among SIVmac, SIVsm, and HIV-2 (Fig.
7), but extreme sequence variation is observed between and
around the clustered N-linked glycosylation sites, including
the neutralizing determinant of MAb SF8/SE11. Furthermore, this region corresponds exactly to an antigenic,
slightly variable (30, 52), weak neutralizing epitope (20) in
HIV-1 TMP which also includes conserved, clustered sites
for N glycosylation (Fig. 7). HIV-1 env aa 612 to 635 (HIV-1
TMP aa 101 to 124) were previously reported by Ho et al.
(20) to be a weak neutralizing epitope.

2014

J. VIROL.

KODAMA ET AL.

SIVmac251

G

G V F V L

F L

G

10
F L A T A G S A K

G

20
A A S L T L T A

V

SIVmacl42

SIVaac239
50
60
251 0 0 L L D V V K R 0 0 E L L R L T V V G T K N L
142
239

251 L N A U G C A

FR

90
100
0 V C H T T V P V P N A

S

L T P

142

239
251
142
239

Q

30

Q

40

S R T L L A G I V 0 0 0

70

80

T R V T A I E K Y L K D 0 A 0

S

D
K

1

NN

120

110

T

H

EV E R K V D

140
130
150
160
L E E N I T A L L E E A 0 I 0 0 E K N M Y E L 0 K L N S U D V F G N U F D L A
A
T

F

Putative anchor domain
251 S V I K Y

I

170

0 Y G

142
239
251 S S P P S Y
142
239

P

I Y V
I
V tJ

180
V G V I L L R I V I

190

Y I VON L A K L R
R

0 G Y R P V

200

F

*
0
0

FIG. 4. Sequence comparison of TMP regions of three SIVmac molecular clones. The predicted amino acid sequences that differ from
SIVmac251 are shown. Overlines indicate potential sites for N-linked glycosylation. Translational in-frame stop codon in SIVmac251 is
indicated by an asterisk. Boxes indicate the positions of amino acids that are unique to SIVmac251.

We next investigated whether genetic changes accumulated in this region following persistent infection of a rhesus
monkey. Rhesus monkey 243-86 was infected with molecularly cloned SIVmac239, developed a strong, stable antibody
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response, and remained persistently infected. We analyzed
16 clones isolated 69 and 93 weeks postinfection directly
from blood, directly from a lymph node biopsy, and from
recovered virus (Fig. 8). All 16 clones displayed amino acid
substitutions arising from individual point mutations within
and around this neutralizing determinant. In this region, 69%
(43 of 62) of the nucleotide substitutions were first- and
second-base changes which changed the amino acid. Eleven
of sixteen clones exhibited an Asn-to-Asp conversion at aa
108 within the determinant defined by SF8/5E11. Interestingly, all seven clones from recovered virus and one clone
from peripheral blood mononuclear cells had Asn at aa 102
instead of the parental Ser; this amino acid substitution
resulted in displacement of one of the potential N-linked
glycosylation sites two codons downstream.

DISCUSSION
The env genes of HIV-1 exhibit significant heterogeneity
at both the nucleotide and deduced amino acid levels. Amino
acid variations appear as clustered mutations interspersed
with polypeptide segments that are highly conserved (45,
52). The conserved regions likely contribute to the stability
of a constant structure and function. Since variable regions
FIG. 5. Identification of the neutralizing determinants recognized by MAb SF8/5E11. (A) Site-specific mutagenesis of SIVmac239. The sequences of oligonucleotide primers and strategy for
SOE are outlined in Materials and Methods. In SIVmac239tm-1, the
Glu at aa 110 was changed to Asp by changing a G-to-T at bp 8764
in the SIVmac239 sequence. In addition to this mutation, the Lys at
aa 106 was changed to Asp in SIVmac239tm-2. (B) Reactivity of
mutant SIVmac239 with MAb. Mutants p239SpE3'tm-1 and -tm-2
were ligated with plasmid p239SpSp5' after digestion with SphI and
transfected separately into CEMx174 cells (See Fig. 6). The virus
was concentrated from the culture supernatants and analyzed for
immunoblot reactivity with MAb SF8/SE11. The size of each TMP is
indicated. Pos. Cont, SIVmac-positive rhesus monkey serum; wt,
parental, wild-type SIVmac239.
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amplified DNA fragment by secondary PCR amplification as outlined in Materials and Methods. OMP, Outer membrane protein.

in the envelope have properties of predicted high antigenicity (30, 45), pressures from the host immune response to
infection may select for variant virus strains. In fact, the
RP135 epitope in hypervariable region V3 of gp120 has been
identified as a major, strain-specific neutralization epitope of
HIV-1 (14, 37, 40). Alignment of the predicted envelope
protein sequences of SIVmac, SIVsm, and HIV-2 also
shows alignment of conserved and variable domains and
apparent conservation of overall structure (3, 15, 18, 54).
The strain-specific neutralizing determinant described in this
report is located within a variable region of the TMP that
includes conserved sites for N-linked glycosylation and is
flanked by conserved domains. This region exactly corresponds to the antigenic, slightly variable (30, 52), weak
neutralizing epitope (20) in the TMP of HIV-1 which also has
conserved N-linked glycosylation sites.
The SIVmac239 molecular clone causes fatal immunodeficiency in approximately 50% of rhesus monkeys within 1
year of infection (24). The strength of the antibody response
in infected monkeys can be predictive of the outcome of
infection; monkeys with weak antibody responses die within
TABLE 2. Syncytium inhibition of mutant SIVmac239tm-2

by SF8/SE11
Syncytium formationa
-SF8/5E11

Virus

+SF8/5E11

SIVmac239
SIVmac239tm-1
SIVmac239tm-2

++
+

++
+
++

a CEMx174 cells were cocultivated with CEMx174 cells infected with
parental cloned SIVmac239 and with mutants SIVmac239tm-1 and
SIVmac239tm-2 in the presence or absence of MAb SF8/5E11. The extent of
syncytium formation was evaluated at 24 h.

6 months with AIDS (7, 24). However, longer-term survivors
with strong antibody responses remain persistently infected
(7, 24). Recent results suggest that genetic variants in env are
selected during persistent infection of rhesus monkeys with
molecularly cloned SIVmac239 (2). All 16 clones that were
analyzed in the current study exhibited extensive sequence
changes within and around the strain-specific neutralizing
determinant defined by MAb SF8/SE11 (Fig. 8). Thus, this
variable, strain-specific, neutralizing determinant is likely to
be a critical target or to interact with a critical target of the
host immune response; flexibility of sequence in this region
may facilitate continued survival and persistence of the virus
in the presence of an active immune response. For two other
lentiviruses, equine infectious anemia virus and visna virus,
progressive changes in the envelope gene have been suggested to be directly responsible for the periodic or chronic
course of the disease (32, 36, 43).
The env gene products of HIV and SIV are heavily
glycosylated proteins, and potential sites of N-linked glycosylation are well conserved (45, 52). The importance of
N-linked glycosylation for early stages of HIV-1 entry has
been described previously (17, 31, 51). Sequence analysis
predicts three potential sites for N-linked glycosylation in
the TMP of SIVmac. These three sites, which are well
conserved in SIVmac, SIVsm, and HIV-2, all cluster around
the neutralizing determinant defined by SF8/SE11. Although
considerable variation in the SIV TMP neutralizing determinant was observed in vivo in our current study, all 16 clones
preserved sites for N-linked glycosylation, including the 8
clones in which one glycosylation site was displaced (Fig. 8).
Tunicamycin treatment demonstrated that carbohydrate
moieties are not involved in recognition by the MAb. Since
the MAb neutralized viral infectivity and inhibited syncytium formation, the aa 106 to 110 region of the TMP is likely
to be important for the viral entry process. Whether
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FIG. 7. Amino acid sequence variation around potential N-linked glycosylation sites of the TMP of SIVmac, SIVsm, and HIV-2. The
predicted amino acid sequences of the TMP region of SIVsm (18), HIV-2ROD (15), HIV-2N1H-z (54), HIV-21sy (11), and HIV-lBHIo (50) are
aligned with those of SIVmac251. The predicted amino acid sequences that differ from SIVmac251 are shown. Boxes indicate potential sites
for N-linked glycosylation. The determinant of recognition by MAb SF8/SE11 is indicated. Envelope protein aa 612 to 635 in HIV-1
correspond to TMP aa 101 to 124 of HIV-1.

murine MAb to HIV-1 gp4l was suggested to require a
contiguous, conformational epitope for recognition (23).
Sequence variation in the 106 to 110 region of SIV TMP
was much more limited in the seven clones from recovered
virus than in the clones directly obtained from peripheral
blood or lymph node (Fig. 8). Therefore, there may be cell
culture selection for particular variants in this region during
the virus recovery and expansion process. Meyerhans et al.
have presented evidence for cell culture selection for individual tat gene variants (29), while Simmonds et al. observed
no cell culture selection for individual gag variants (44).
Several functional epitopes in the TMP of HIV-1 have
been identified previously, including a fusion domain (13,
28), neutralization epitope (4, 5, 20), immunosuppressive
domain (26, 39), and cytotoxic T-lymphocyte epitope (46).
The fusion domain of SIVmac has been localized to the
amino terminus of the TMP (1), just as in HIV-1. However,
other functional domains of SIV TMP have not been identified. The strain-specific neutralizing determinant in the variable region of SIVmac TMP demonstrated in this report
corresponds in location to a variable, neutralizing epitope
previously identified in HIV-1. Thus, the location of at least
one neutralizing epitope appears to be common to both
SIVmac and HIV-1. Continued studies along these lines will
be important for validating SIV models for vaccine develop-

N-linked carbohydrates in this region may also play a role in
early stages of virus entry, possibly in recognition of a
cellular receptor or in fusion with host cell membranes, is
currently under investigation.
At present, it is not obvious why the size of the TMP and
the ability of virus to form syncytia were altered by the
mutation at TMP codon 110 in SIVmac239tm-1. The single
amino acid substitution at TMP position 110 could possibly
affect the extent or nature of the glycosylation and thus alter
its mobility through SDS-polyacrylamide gels. It is tempting
to speculate whether the reduced capacity for syncytium
formation by SIVmac239tm-1 may be related to altered
glycosylation in the aa 106 to 110 region of the TMP.
Our results indicate that SIVmac TMP aa 106 to 110 are
essential for formation of the epitope recognized by MAb
SF8/SE11. However, we were not able to demonstrate
specific reactivity of MAb SF8/SE11 to 25-amino-acid-long
peptides spanning the region of interest nor to E. coli
recombinant libraries making viral fusion proteins. It is still
possible that the MAb directly recognizes sequences around
TMP positions 106 to 110, but this recognition may be highly
dependent on secondary structure that is not reproduced in
synthetic peptides or E. coli recombinant protein. Alternatively, it is possible that MAb SF8/SE11 recognizes a complex
conformational epitope or a distal epitope whose secondary
structure is influenced by the 106 to 110 region. Recently, a
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FIG. 8. In vivo genetic drift of the SIVmac TMP variable region. T69 and T93 refer to the number of weeks postinfection of cloned
SIVmac239. Sources of DNA for PCR amplification were blood (BL), lymph node (LN), and recovered virus (V). The predicted amino acid
sequences that differ from SIVmac239 are shown. Potential sites for N-linked glycosylation are indicated by boxes. The asterisk indicates a
translational in-frame stop codon.
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ment and will hopefully shed light on fundamental principles
of virus entry, replication, and pathogenesis.
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